四川医学
四川醫學
사천의학
SICHUAN MEDICAL JOURNAL
2014年
4期
452-454
,共3页
郑琼%张道进%杨阳%何北海
鄭瓊%張道進%楊暘%何北海
정경%장도진%양양%하북해
急性冠状动脉综合征%阿托伐他汀%强化降脂%安全性
急性冠狀動脈綜閤徵%阿託伐他汀%彊化降脂%安全性
급성관상동맥종합정%아탁벌타정%강화강지%안전성
acute coronary artery syndrome%atorvastatin%intensive lipid-lowering%safety
目的:观察急性冠状动脉综合征( ACS)早期应用不同剂量的阿托伐他汀的临床疗效及安全性。方法选择临床确诊为ACS的患者共80例,随机分为10 mg组和40 mg组,每晚服药1次,观察4周、12周后的血脂和高敏C-反应蛋白( hsCRP),随访3个月内的不良反应及心脏事件的发生率。结果①两组服药后4周、12周的总胆固醇( TC)、低密度脂蛋白(LDL-C)、hsCRp水平40 mg组比10 mg组降低更明显,两组比较差异有统计学意义,P<0.05。②两组均无严重不良反应。结论 ACS早期应用40 mg阿托伐他汀能够更有效地降低TC和LDL-C水平,降低炎症因子,且具有良好的安全性。
目的:觀察急性冠狀動脈綜閤徵( ACS)早期應用不同劑量的阿託伐他汀的臨床療效及安全性。方法選擇臨床確診為ACS的患者共80例,隨機分為10 mg組和40 mg組,每晚服藥1次,觀察4週、12週後的血脂和高敏C-反應蛋白( hsCRP),隨訪3箇月內的不良反應及心髒事件的髮生率。結果①兩組服藥後4週、12週的總膽固醇( TC)、低密度脂蛋白(LDL-C)、hsCRp水平40 mg組比10 mg組降低更明顯,兩組比較差異有統計學意義,P<0.05。②兩組均無嚴重不良反應。結論 ACS早期應用40 mg阿託伐他汀能夠更有效地降低TC和LDL-C水平,降低炎癥因子,且具有良好的安全性。
목적:관찰급성관상동맥종합정( ACS)조기응용불동제량적아탁벌타정적림상료효급안전성。방법선택림상학진위ACS적환자공80례,수궤분위10 mg조화40 mg조,매만복약1차,관찰4주、12주후적혈지화고민C-반응단백( hsCRP),수방3개월내적불량반응급심장사건적발생솔。결과①량조복약후4주、12주적총담고순( TC)、저밀도지단백(LDL-C)、hsCRp수평40 mg조비10 mg조강저경명현,량조비교차이유통계학의의,P<0.05。②량조균무엄중불량반응。결론 ACS조기응용40 mg아탁벌타정능구경유효지강저TC화LDL-C수평,강저염증인자,차구유량호적안전성。
Objective To observe the effect of acute coronary syndrome ( ACS) clinical efficacy and safety of early appli-cation of different doses of atorvastatin. Methods the clinical diagnosis of acute coronary syndrome patients with a total of 80 ca-ses, were randomly divided into 10mg group and 40m group, nightly medication time, blood lipid and high sensitive C- reactive protein in 4 weeks, 12 weeks ( hsCRP) , the incidence of adverse reactions and cardiac events were followed up for 3 months the. Results ①Two groups after 4 weeks, 12 weeks of total cholesterol, low density lipoprotein, the level of hsCRp 40 mg in group mg than in group mg decreased more significantly in 10 mg, there was significant difference between two groups (P<0. 05). ②The two groups had no serious adverse reactions. Conclusion Acute coronary syndrome (ACS) 40m g early application atorvas-tatin can effectively reduce the total cholesterol ( TC) and low density lipoprotein cholesterol ( LDL-C) levels, reduce inflammatory factors, and has a good safety.